JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB273385

Crenolanib (CP-868596)

Be the first to review this product! Submit a review

|

(0 Publication)

MW 443.5 Da, Purity 97%. Potent inhibitor of PDGFR (Kd for alpha = 2.1 nM; beta = 3.2 nM) and FLT3 (Kd = 0.74 nM). Type I inhibitor that binds only the active kinase conformation. Active towards imatinib-resistance assciated PDGFR-alpha mutations (D842I, D842V, D842Y, DI842-843M, and deletion I843). Active against FLT3/ITD and FLY3/D835 mutatants. Over 100-fold selective for PDGFR versus c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.

View Alternative Names

AP 4 A synthetase, CAM kinase II delta, CAMK 2, CAMK 2B, CAMK 2d, CAMK2G, CAMKA, CMT2D, CaM kinase II, CaM kinase II alpha, CaM kinase II beta, CaM kinase II gamma, CaM kinase II subunit alpha, CaMK-II subunit alpha, Calcium / calmodulin dependent protein kinase II delta, Calcium/calmodulin dependent protein kinase II gamma, Calcium/calmodulin-dependent protein kinase II-alpha, Calcium/calmodulin-dependent protein kinase type II subunit alpha, Camk2a, Charcot Marie Tooth neuropathy 2D, Charcot Marie Tooth neuropathy neuronal type D, DSMAV, Diadenosine tetraphosphate synthetase, EC 2.7.11.1, EC 6.1.1.14, GSD9C, Germinal center kinase like kinase, Germinal center kinase-related protein kinase, GlyRS, Glycine tRNA ligase, Glycyl tRNA synthetase, HMN5, KCC2A_HUMAN, KHS, Kinase homologous to SPS1/STE20, MAP4K3, MAPK/ERK kinase kinase kinase 3, MAPK/ERK kinase kinase kinase 5, MAPKKKK3, MEK kinase kinase 3, MEK kinase kinase 5, MEKKK 3, MEKKK 5, PHK gamma LT, PHK gamma T, PSK C3, Phosphorylase b kinase gamma catalytic chain testis/liver isoform, Phosphorylase b kinase gamma catalytic chain, liver/testis isoform, Phosphorylase kinase catalytic subunit gamma 2, Phosphorylase kinase gamma subunit 2, Phosphorylase kinase subunit gamma 2, Phosphorylase kinase, gamma 2 (testis), Phosphorylase kinase, gamma 2 (testis/liver), RAB8IPL1, Serine/threonine protein kinase PHKG2, calcium/calmodulin-dependent protein kinase II beta, mitogen-activated protein kinase kinase kinase kinase 3

1 Images
Chemical Structure - Crenolanib (CP-868596) (AB273385)
  • Chemical Structure

Lab

Chemical Structure - Crenolanib (CP-868596) (AB273385)

Chemical structure of Crenolanib (CP-868596), 670220-88-9

Key facts

CAS number

670220-88-9

Purity

97%

Form

Solid

form

Molecular weight

443.5 Da

Molecular formula

C<sub>2</sub><sub>6</sub>H<sub>2</sub><sub>9</sub>N<sub>5</sub>O<sub>2</sub>

PubChem

10366136

Nature

Synthetic

Solubility

Soluble in DMSO to 25 mM

Soluble in ethanol to 10 mM

Biochemical name

Crenolanib

Biological description

Potent inhibitor of PDGFR (Kd for alpha = 2.1 nM; beta = 3.2 nM) and FLT3 (Kd = 0.74 nM). Type I inhibitor that binds only the active kinase conformation. Active towards imatinib-resistance assciated PDGFR-alpha mutations (D842I, D842V, D842Y, DI842-843M, and deletion I843). Active against FLT3/ITD and FLY3/D835 mutatants. Over 100-fold selective for PDGFR versus c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.

Canonical smiles

CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4

InChi

InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3

InChiKey

DYNHJHQFHQTFTP-UHFFFAOYSA-N

IUPAC Name

1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylase kinase gamma 2 (PHKG2) mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5) MAP4K3/GLK (germinal center kinase-like kinase) and glycyl-tRNA synthetase (GARS) are distinct but functionally significant proteins in cellular signaling and metabolism. CaMKII also known as CAM2K exhibits a mass approximately of 50-60 kDa and expresses in many tissues especially in the brain and heart. PHKG2 with a mass around 44 kDa participates mainly in liver and skeletal muscles. MAP4K5 and MAP4K3 also known as KHS and GLK respectively express throughout various tissues with masses near 100 kDa. GARS a component of the aminoacyl-tRNA synthetase family weighs about 83 kDa and shows presence in cytoplasm.
Biological function summary

These proteins serve as significant modulators of cellular activities. CaMKII plays a role in calcium ion signaling and associates with L-type calcium channel complex enhancing signal transduction. PHKG2 regulates glycogen metabolism being part of a complex involved in glycogen breakdown. MAP4K5 and MAP4K3 function in stress-activated protein kinase pathways taking part in immune responses and cell apoptosis. GARS joins protein synthesis machinery by catalyzing the attachment of glycine to its corresponding transfer RNA.

Pathways

These proteins integrate into essential signaling and metabolic routes. CaMKII influences the calcium/calmodulin signaling pathway affecting brain functions and cardiac contractility relating closely to proteins like calmodulin and synapsin. PHKG2 fits into the glycogen degradation pathway interacting with partners such as phosphorylase kinase beta. MAP4K5 and MAP4K3 engage in the JNK signaling cascade essential for inflammatory response linking with MAPK and AP-1 transcription factors. GARS operates within the protein biosynthesis pathway connecting to elongation factors to ensure accurate amino acid incorporation.

These proteins exhibit associations with various pathological states. CaMKII relates to cardiac hypertrophy and Alzheimer’s disease with links to tau protein contributing to neurofibrillary tangles. Mutations in PHKG2 cause glycogen storage disease type IXa affecting energy metabolism and interacting with the enzyme glycogen phosphorylase. MAP4K5 and MAP4K3 show connections to inflammatory bowel disease due to their role in JNK-mediated inflammation. GARS mutations lead to Charcot-Marie-Tooth disease a peripheral neuropathy disorder involving connections to protein misfolding pathways.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com